Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2024-09-12 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding amendments to the company's Articles of Association (公司章程). It includes extensive revisions to governance rules, shareholder rights, board responsibilities, capital changes, and operational scope. The content focuses on corporate governance structure and internal rules rather than financial results or audit opinions. There is no indication of financial statements, earnings data, or audit reports. The document is not a brief announcement but a substantive governance-related disclosure. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-09-12 Chinese
益丰药房关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 益丰大药房连锁股份有限公司 regarding the increase of the company's comprehensive bank credit lines. It details the amounts of credit increases requested from various banks, the original and new credit limits, and whether collateral is provided. The document is dated September 13, 2024, and is signed by the company's board of directors. There is no financial statement, earnings data, or detailed financial analysis present. The document is an update on financing activities, specifically about bank credit facilities. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement since it contains substantive information about financing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1799 characters), but it contains detailed financing information rather than just an announcement of a report publication or certification.
2024-09-12 Chinese
益丰药房第五届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 益丰大药房连锁股份有限公司 regarding approval of financial matters such as increasing self-owned funds for wealth management, increasing bank credit limits, and guarantees for subsidiaries' bank credit applications. It is a formal meeting resolution announcement with voting results and no financial statements or detailed financial data. The document length is short (1309 characters) and it is not a financial report but a corporate governance announcement related to board decisions. Therefore, it fits best under Board/Management Information (MANG).
2024-09-12 Chinese
益丰药房关于使用闲置募集资金委托理财到期赎回并继续委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding the redemption and continued entrustment of idle raised funds into financial products. It details the amounts, types of financial products, risk analysis, and board approval. The document is relatively short (3123 characters) and focuses on the company's use of idle raised funds for entrusted financial management, including risk disclosures and procedural approvals. It does not contain financial statements or comprehensive financial data, nor is it a full report like an annual or interim report. It is a specific update on capital usage and financing activities related to raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-09-03 Chinese
益丰药房关于“益丰转债”开始转股的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the start of the conversion period for its convertible bonds (可转债). It details the terms of the convertible bonds, including the conversion price, conversion period, issuance details, and procedures for bondholders to convert bonds into shares. The document references regulatory approvals and stock exchange listings but does not contain financial statements or performance data. The length is about 3500 characters, which is relatively short and typical for an announcement. It is not a full financial report, audit, or earnings release. It is also not a proxy, voting result, or management change announcement. The content is focused on capital structure update related to convertible bonds and their conversion terms. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-03 Chinese
益丰药房投资者关系活动会议纪要（20240902）
Call Transcript Classification · 95% confidence The document is a detailed transcript of an investor relations activity meeting held by 益丰大药房连锁股份有限公司 on August 31, 2024. It includes comprehensive discussion of the company's 2024 half-year operating results, business updates, strategic outlook, and Q&A with investors. The content contains substantive financial data such as revenue, net profit, store counts, and dividend distribution, as well as management commentary on business trends and future plans. The format and content align with a conference call or investor meeting transcript rather than a formal earnings release or annual/interim report. Therefore, the document best fits the category of a Call Transcript (CT). The document length (2419 characters) is consistent with a detailed transcript rather than a brief announcement or report publication notice.
2024-09-02 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.